{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:49:47Z","timestamp":1785890987718,"version":"3.56.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiopulmonary involvement in systemic lupus erythematosus (SLE) refers to a group of serious manifestations, with a high prevalence for some, such as pericarditis and pleuritis, and high mortality in others, such as lupus myocarditis (LM) and diffuse alveolar haemorrhage (DAH). There is a paucity of systematic literature reviews on the management of inflammatory cardiopulmonary manifestations in SLE. We aimed to assess the available evidence in this area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was conducted from January 1990 to June 2025 using keywords related to the cardiac and pulmonary systems, SLE, and treatments. Manifestations related to atherosclerosis or anti-phospholipid syndrome were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 67 studies, covering pericarditis, LM, pulmonary arterial hypertension (PAH), pleuritis, acute lupus pneumonitis (ALP), DAH, interstitial lung disease, and shrinking lung syndrome (SLS) were included. Glucocorticoids (GCs) were utilized as first-line treatment for all these conditions, and GC pulse was commonly administered in serious manifestations such as pericardial tamponade, LM, ALP, and DAH. Cyclophosphamide was the most used immunosuppressant, with low-to-moderate evidence indicating its effectiveness. Low-to-moderate evidence supported rituximab as a second-line therapy for LM, DAH, and SLS, and plasma exchange was commonly used in DAH. For PAH, high-quality evidence from RCTs supported the use of PAH-targeted therapies, and initial PAH-targeted combination therapy showed more benefits than monotherapy. In addition, immunosuppressive therapy may be beneficial for SLE-PAH patients, especially those with early, mild PAH. Anti-fibrotic therapy, such as nintedanib and pirfenidone, had no evidence of effectiveness in SLE-ILD. Evidence for the benefit of belimumab and anifrolumab for cardiopulmonary manifestations was also minimal. Patients with some conditions, such as LM, ALP, and DAH, had poor prognoses under current therapies, with reported short-term mortalities of up to 40%-60%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GC and conventional IS currently remain the most evidence-based approaches for managing most cardiopulmonary manifestations in SLE. Despite aggressive immunosuppressive therapies, patients with some conditions, such as LM, ALP, and DAH, still experience high mortality. The quality of the existing evidence and the insights into novel therapies in these patients were limited, highlighting the urgent need for RCTs and optimized management in this area.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-026-00551-1","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:34:46Z","timestamp":1780043686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of inflammatory cardiopulmonary manifestations in systemic lupus erythematosus: a systematic review"],"prefix":"10.1186","volume":"66","author":[{"given":"Yanjie","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Oon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-5611","authenticated-orcid":false,"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"2","key":"551_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/acr.24431","volume":"74","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, O\u2019Neill S, Li M, Tsai IC, Yang YW. Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region. Arthritis Care Res (Hoboken). 2022;74(2):187\u201398.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"551_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0961203315627202","volume":"25","author":"YH Lee","year":"2016","unstructured":"Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25(7):727\u201334.","journal-title":"Lupus"},{"issue":"1","key":"551_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/CRD.0000000000000358","volume":"30","author":"NK Zagelbaum Ward","year":"2022","unstructured":"Zagelbaum Ward NK, Linares-Koloffon C, Posligua A, Gandrabur L, Kim WY, Sperber K, et al. Cardiac Manifestations of Systemic Lupus Erythematous: An Overview of the Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology and Treatment Options. Cardiol Rev. 2022;30(1):38\u201343.","journal-title":"Cardiol Rev"},{"key":"551_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jcm11226714","volume":"11","author":"JI Shin","year":"2022","unstructured":"Shin JI, Lee KH, Park S, Yang JW, Kim HJ, Song K, et al. Systemic Lupus Erythematosus and Lung Involvement: A Comprehensive Review. J Clin Med. 2022;11:22.","journal-title":"J Clin Med"},{"issue":"1","key":"551_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13075-018-1776-8","volume":"20","author":"J Narvaez","year":"2018","unstructured":"Narvaez J, Borrell H, Sanchez-Alonso F, Rua-Figueroa I, Lopez-Longo FJ, Galindo-Izquierdo M, et al. Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. Arthritis Res Ther. 2018;20(1):280.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"551_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1191\/0961203305lu2200oa","volume":"14","author":"A Doria","year":"2005","unstructured":"Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14(9):683\u20136.","journal-title":"Lupus"},{"issue":"2","key":"551_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0039-1685537","volume":"40","author":"JR Hannah","year":"2019","unstructured":"Hannah JR, D\u2019Cruz DP. Pulmonary Complications of Systemic Lupus Erythematosus. Semin Respir Crit Care Med. 2019;40(2):227\u201334.","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"551_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-016-0571-2","volume":"18","author":"CE Fors Nieves","year":"2016","unstructured":"Fors Nieves CE, Izmirly PM. Mortality in Systemic Lupus Erythematosus: an Updated Review. Curr Rheumatol Rep. 2016;18(4):21.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"551_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0002-9343(81)90366-1","volume":"71","author":"HM Haupt","year":"1981","unstructured":"Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med. 1981;71(5):791\u20138.","journal-title":"Am J Med"},{"issue":"7","key":"551_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/jcp.2009.064311","volume":"62","author":"D Jain","year":"2009","unstructured":"Jain D, Halushka MK. Cardiac pathology of systemic lupus erythematosus. J Clin Pathol. 2009;62(7):584\u201392.","journal-title":"J Clin Pathol"},{"issue":"7","key":"551_CR11","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1016\/S2665-9913(25)00063-3","volume":"7","author":"L Arnaud","year":"2025","unstructured":"Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall\u2019Era M, Adelowo O, et al. ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Lancet Rheumatol. 2025;7(7):e505\u201318.","journal-title":"Lancet Rheumatol"},{"issue":"9767","key":"551_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331.","journal-title":"Lancet"},{"issue":"12","key":"551_CR13","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"551_CR14","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","volume":"71","author":"S Manzi","year":"2012","unstructured":"Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"551_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271\u20137.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"551_CR16","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"551_CR17","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"551_CR18","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400\u201312.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"551_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/art.1780351115","volume":"35","author":"LE Kahl","year":"1992","unstructured":"Kahl LE. The spectrum of pericardial tamponade in systemic lupus erythematosus. Report of ten patients. Arthritis Rheum. 1992;35(11):1343\u20139.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"551_CR20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1191\/0961203305lu2187oa","volume":"14","author":"BL Man","year":"2005","unstructured":"Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus. 2005;14(10):822\u20136.","journal-title":"Lupus"},{"issue":"1","key":"551_CR21","first-page":"55","volume":"10","author":"Y Sherer","year":"2008","unstructured":"Sherer Y, Kuechler S, Jose Scali J, Rovensky J, Levy Y, Zandman-Goddard G, Shoenfeld Y. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J. 2008;10(1):55\u20137.","journal-title":"Isr Med Assoc J"},{"issue":"4","key":"551_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10067-009-1090-6","volume":"28","author":"MS Ngandeu","year":"2009","unstructured":"Ngandeu MS, Ndobo P, Gabay C. Non-infectious lupus pericarditis: a retrospective hospital-based observation in Yaounde-Cameroon. Clin Rheumatol. 2009;28(4):465\u20138.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"551_CR23","first-page":"1234","volume":"97","author":"T Buppajamrntham","year":"2014","unstructured":"Buppajamrntham T, Palavutitotai N, Katchamart W. Clinical manifestation, diagnosis, management, and treatment outcome of pericarditis in patients with systemic lupus erythematosus. J Med Assoc Thai. 2014;97(12):1234\u201340.","journal-title":"J Med Assoc Thai"},{"issue":"2","key":"551_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/qjmed\/hcx195","volume":"111","author":"RP Goswami","year":"2018","unstructured":"Goswami RP, Sircar G, Ghosh A, Ghosh P. Cardiac tamponade in systemic lupus erythematosus. QJM. 2018;111(2):83\u20137.","journal-title":"QJM"},{"issue":"6","key":"551_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1191\/0961203305lu2131oa","volume":"14","author":"HS Weich","year":"2005","unstructured":"Weich HS, Burgess LJ, Reuter H, Brice EA, Doubell AF. Large pericardial effusions due to systemic lupus erythematosus: a report of eight cases. Lupus. 2005;14(6):450\u20137.","journal-title":"Lupus"},{"issue":"14","key":"551_CR26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1177\/0961203315593169","volume":"24","author":"N Morel","year":"2015","unstructured":"Morel N, Bonjour M, Le Guern V, Le Jeunne C, Mouthon L, Piette JC, Costedoat-Chalumeau N. Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases. Lupus. 2015;24(14):1479\u201385.","journal-title":"Lupus"},{"issue":"5","key":"551_CR27","first-page":"1115","volume":"42","author":"A Fava","year":"2024","unstructured":"Fava A, Cammarata M, Adamo L. Rilonacept use in lupus pericarditis. Clin Exp Rheumatol. 2024;42(5):1115\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"551_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3899\/jrheum.160493","volume":"44","author":"G Thomas","year":"2017","unstructured":"Thomas G, Cohen Aubart F, Chiche L, Haroche J, Hie M, Hervier B, et al. Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients. J Rheumatol. 2017;44(1):24\u201332.","journal-title":"J Rheumatol"},{"issue":"1","key":"551_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/0961203316651741","volume":"26","author":"R Du Toit","year":"2017","unstructured":"Du Toit R, Herbst PG, van Rensburg A, du Plessis LM, Reuter H, Doubell AF. Clinical features and outcome of lupus myocarditis in the Western Cape, South Africa. Lupus. 2017;26(1):38\u201347.","journal-title":"Lupus"},{"issue":"8","key":"551_CR30","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1177\/0961203318770018","volume":"27","author":"J Tanwani","year":"2018","unstructured":"Tanwani J, Tselios K, Gladman DD, Su J, Urowitz MB. Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies. Lupus. 2018;27(8):1296\u2013302.","journal-title":"Lupus"},{"issue":"6","key":"551_CR31","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s10067-017-3971-4","volume":"37","author":"CR Wang","year":"2018","unstructured":"Wang CR, Tsai YS, Li WT. Lupus myocarditis receiving the rituximab therapy-a monocentric retrospective study. Clin Rheumatol. 2018;37(6):1701\u20137.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"551_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1191\/0961203305lu2228oa","volume":"14","author":"WG Law","year":"2005","unstructured":"Law WG, Thong BY, Lian TY, Kong KO, Chng HH. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus. 2005;14(10):827\u201331.","journal-title":"Lupus"},{"issue":"3","key":"551_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00296-007-0414-6","volume":"28","author":"JW Chung","year":"2008","unstructured":"Chung JW, Joe DY, Park HJ, Kim HA, Park HS, Suh CH. Clinical characteristics of lupus myocarditis in Korea. Rheumatol Int. 2008;28(3):275\u201380.","journal-title":"Rheumatol Int"},{"issue":"9","key":"551_CR34","first-page":"295","volume":"67","author":"NE van der Laan-Baalbergen","year":"2009","unstructured":"van der Laan-Baalbergen NE, Mollema SA, Kritikos H, Schoe A, Huizinga TW, Bax JJ, et al. Heart failure as presenting manifestation of cardiac involvement in systemic lupus erythematosus. Neth J Med. 2009;67(9):295\u2013301.","journal-title":"Neth J Med"},{"issue":"13","key":"551_CR35","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1177\/0961203312456752","volume":"21","author":"GM Zawadowski","year":"2012","unstructured":"Zawadowski GM, Klarich KW, Moder KG, Edwards WD, Cooper LT. Jr. A contemporary case series of lupus myocarditis. Lupus. 2012;21(13):1378\u201384.","journal-title":"Lupus"},{"issue":"9","key":"551_CR36","first-page":"1650","volume":"40","author":"H Liu","year":"2022","unstructured":"Liu H, Chen Y, Zhao L, Liu Y, Wang Y, Tian X, et al. Clinical characteristics and outcomes of lupus myocarditis: a retrospective case control study in Chinese patients. Clin Exp Rheumatol. 2022;40(9):1650\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"551_CR37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1378\/chest.126.2.420","volume":"126","author":"RJ Oudiz","year":"2004","unstructured":"Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126(2):420\u20137.","journal-title":"Chest"},{"issue":"2","key":"551_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1191\/0961203304lu509oa","volume":"13","author":"L Gonzalez-Lopez","year":"2004","unstructured":"Gonzalez-Lopez L, Cardona-Munoz EG, Celis A, Garcia-de la Torre I, Orozco-Barocio G, Salazar-Paramo M, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus. 2004;13(2):105\u201312.","journal-title":"Lupus"},{"issue":"10","key":"551_CR39","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1136\/ard.2005.048967","volume":"65","author":"CP Denton","year":"2006","unstructured":"Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006;65(10):1336\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"551_CR40","first-page":"2417","volume":"34","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34(12):2417\u201322.","journal-title":"J Rheumatol"},{"issue":"11","key":"551_CR41","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/ard.2007.069609","volume":"66","author":"RE Girgis","year":"2007","unstructured":"Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis. 2007;66(11):1467\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"551_CR42","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"Coghlan JG, Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76(7):1219\u201327.","journal-title":"Ann Rheum Dis"},{"key":"551_CR43","doi-asserted-by":"crossref","unstructured":"Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galie N, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50(2).","DOI":"10.1183\/13993003.02493-2016"},{"issue":"2","key":"551_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","volume":"76","author":"M Humbert","year":"2017","unstructured":"Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017;76(2):422\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"551_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/1756-185X.12409","volume":"18","author":"Y Chen","year":"2015","unstructured":"Chen Y, Guo L, Li Y, Chen GL, Chen XX, Ye S. Severe pulmonary arterial hypertension secondary to lupus in the emergency department: proactive intense care associated with a better short-term survival. Int J Rheum Dis. 2015;18(3):331\u20135.","journal-title":"Int J Rheum Dis"},{"issue":"Suppl 3","key":"551_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2362.2006.01684.x","volume":"36","author":"F Cozzi","year":"2006","unstructured":"Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest. 2006;36(Suppl 3):49\u201353.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"551_CR47","first-page":"282","volume":"29","author":"E Tanaka","year":"2002","unstructured":"Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol. 2002;29(2):282\u20137.","journal-title":"J Rheumatol"},{"issue":"1","key":"551_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1378\/chest.130.1.182","volume":"130","author":"O Sanchez","year":"2006","unstructured":"Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130(1):182\u20139.","journal-title":"Chest"},{"issue":"10","key":"551_CR49","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.rmed.2007.05.020","volume":"101","author":"GA Heresi","year":"2007","unstructured":"Heresi GA, Minai OA. Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy. Respir Med. 2007;101(10):2099\u2013107.","journal-title":"Respir Med"},{"issue":"2","key":"551_CR50","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/art.23303","volume":"58","author":"X Jais","year":"2008","unstructured":"Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58(2):521\u201331.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"551_CR51","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1253\/circj.CJ-11-0473","volume":"75","author":"S Miyamichi-Yamamoto","year":"2011","unstructured":"Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, Ishii T, Satoh K, Miura Y, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J. 2011;75(11):2668\u201374.","journal-title":"Circ J"},{"issue":"10","key":"551_CR52","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/rheumatology\/kes140","volume":"51","author":"Y Shirai","year":"2012","unstructured":"Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. Rheumatology (Oxford). 2012;51(10):1846\u201354.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"551_CR53","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/rheumatology\/kev097","volume":"54","author":"S Kommireddy","year":"2015","unstructured":"Kommireddy S, Bhyravavajhala S, Kurimeti K, Chennareddy S, Kanchinadham S, Rajendra Vara Prasad I, Rajasekhar L. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. Rheumatology (Oxford). 2015;54(9):1673\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"551_CR54","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1253\/circj.CJ-17-0351","volume":"82","author":"H Yasuoka","year":"2018","unstructured":"Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M. Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Circ J. 2018;82(2):546\u201354.","journal-title":"Circ J"},{"key":"551_CR55","doi-asserted-by":"crossref","unstructured":"Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, et al. Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Eur Respir J. 2019;53(2).","DOI":"10.1183\/13993003.00081-2018"},{"issue":"4","key":"551_CR56","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/rheumatology\/kead360","volume":"63","author":"O Distler","year":"2024","unstructured":"Distler O, Ofner C, Huscher D, Jordan S, Ulrich S, Stahler G, et al. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis. Rheumatology (Oxford). 2024;63(4):1139\u201346.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"551_CR57","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13075-024-03338-1","volume":"26","author":"Y Li","year":"2024","unstructured":"Li Y, Qian J, Dong X, Zhao J, Wang Q, Wang Y, et al. The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC\/ERS guidelines. Arthritis Res Ther. 2024;26(1):109.","journal-title":"Arthritis Res Ther"},{"key":"551_CR58","doi-asserted-by":"crossref","unstructured":"Luppino-Assad AP, Alves Junior JL, Figueiredo Neves Yuki E, Seguro LPC, Pasoto SG, Fernandes C, et al. Reversibility of pulmonary hypertension in systemic lupus erythematosus after induction immunosuppressive therapy: An inflammatory manifestation? Lupus. 2025;34(1):18\u201327.","DOI":"10.1177\/09612033241301183"},{"issue":"1","key":"551_CR59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1378\/chest.117.1.14","volume":"117","author":"IM Robbins","year":"2000","unstructured":"Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000;117(1):14\u20138.","journal-title":"Chest"},{"issue":"8","key":"551_CR60","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/RHU.0000000000000179","volume":"20","author":"N Palavutitotai","year":"2014","unstructured":"Palavutitotai N, Buppajarntham T, Katchamart W. Etiologies and outcomes of pleural effusions in patients with systemic lupus erythematosus. J Clin Rheumatol. 2014;20(8):418\u201321.","journal-title":"J Clin Rheumatol"},{"issue":"13","key":"551_CR61","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1177\/0961203316646461","volume":"25","author":"SA Wan","year":"2016","unstructured":"Wan SA, Teh CL, Jobli AT. Lupus pneumonitis as the initial presentation of systemic lupus erythematosus: case series from a single institution. Lupus. 2016;25(13):1485\u201390.","journal-title":"Lupus"},{"issue":"5","key":"551_CR62","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/096120339700600506","volume":"6","author":"LA Barile","year":"1997","unstructured":"Barile LA, Jara LJ, Medina-Rodriguez F, Garcia-Figueroa JL, Miranda-Limon JM. Pulmonary hemorrhage in systemic lupus erythematosus. Lupus. 1997;6(5):445\u20138.","journal-title":"Lupus"},{"issue":"6","key":"551_CR63","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.semarthrit.2003.09.006","volume":"33","author":"H Badsha","year":"2004","unstructured":"Badsha H, Teh CL, Kong KO, Lian TY, Chng HH. Pulmonary hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum. 2004;33(6):414\u201321.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"551_CR64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0961203315605365","volume":"25","author":"C Andrade","year":"2016","unstructured":"Andrade C, Mendonca T, Farinha F, Correia J, Marinho A, Almeida I, Vasconcelos C. Alveolar hemorrhage in systemic lupus erythematosus: a cohort review. Lupus. 2016;25(1):75\u201380.","journal-title":"Lupus"},{"issue":"5","key":"551_CR65","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/03009742.2017.1420817","volume":"47","author":"CR Wang","year":"2018","unstructured":"Wang CR, Liu MF, Weng CT, Lin WC, Li WT, Tsai HW. Systemic lupus erythematosus-associated diffuse alveolar haemorrhage: a single-centre experience in Han Chinese patients. Scand J Rheumatol. 2018;47(5):392\u20139.","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"551_CR66","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/0961203320920715","volume":"29","author":"Y Sun","year":"2020","unstructured":"Sun Y, Zhou C, Zhao J, Wang Q, Xu D, Zhang S, et al. Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China. Lupus. 2020;29(7):795\u2013803.","journal-title":"Lupus"},{"issue":"3","key":"551_CR67","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00005792-199705000-00005","volume":"76","author":"MR Zamora","year":"1997","unstructured":"Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Med (Baltim). 1997;76(3):192\u2013202.","journal-title":"Med (Baltim)"},{"issue":"4","key":"551_CR68","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1378\/chest.118.4.1083","volume":"118","author":"AS Santos-Ocampo","year":"2000","unstructured":"Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest. 2000;118(4):1083\u201390.","journal-title":"Chest"},{"issue":"11","key":"551_CR69","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s10067-007-0576-3","volume":"26","author":"C Canas","year":"2007","unstructured":"Canas C, Tobon GJ, Granados M, Fernandez L. Diffuse alveolar hemorrhage in Colombian patients with systemic lupus erythematosus. Clin Rheumatol. 2007;26(11):1947\u20139.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"551_CR70","doi-asserted-by":"publisher","first-page":"e000117","DOI":"10.1136\/lupus-2015-000117","volume":"2","author":"NM Kazzaz","year":"2015","unstructured":"Kazzaz NM, Coit P, Lewis EE, McCune WJ, Sawalha AH, Knight JS. Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival. Lupus Sci Med. 2015;2(1):e000117.","journal-title":"Lupus Sci Med"},{"issue":"6","key":"551_CR71","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s10067-023-06517-8","volume":"42","author":"M Li","year":"2023","unstructured":"Li M, Bai W, Wang Y, Song L, Zhang S, Zhao J, et al. Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a potential key to improve outcomes. Clin Rheumatol. 2023;42(6):1573\u201384.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"551_CR72","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s00296-024-05684-4","volume":"44","author":"MJ Garcia-Villanueva","year":"2024","unstructured":"Garcia-Villanueva MJ, Garrote-Corral S, Pego-Reigosa JM, Jimenez Otero N, Uriarte Isazelaia E, Olive Marque A, et al. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER). Rheumatol Int. 2024;44(11):2445\u201355.","journal-title":"Rheumatol Int"},{"issue":"8","key":"551_CR73","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1177\/09612033231180704","volume":"32","author":"AH Law","year":"2023","unstructured":"Law AH, Chuah TY, Lee W, Teng GG, Lian TY, Saffari SE, Chew LC. Diffuse alveolar haemorrhage in systemic lupus erythematosus: A multicentre retrospective study in Singapore. Lupus. 2023;32(8):952\u201363.","journal-title":"Lupus"},{"key":"551_CR74","doi-asserted-by":"publisher","first-page":"871861","DOI":"10.3389\/fmed.2022.871861","volume":"9","author":"J Wang","year":"2022","unstructured":"Wang J, Wang X, Qi X, Sun Z, Zhang T, Cui Y, Shu Q. The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study. Front Med (Lausanne). 2022;9:871861.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"551_CR75","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.121043","volume":"40","author":"A Fischer","year":"2013","unstructured":"Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640\u20136.","journal-title":"J Rheumatol"},{"key":"551_CR76","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","volume":"121","author":"JM Oldham","year":"2016","unstructured":"Oldham JM, Lee C, Valenzi E, Witt LJ, Adegunsoye A, Hsu S, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016;121:117\u201322.","journal-title":"Respir Med"},{"issue":"1","key":"551_CR77","doi-asserted-by":"publisher","first-page":"20230838","DOI":"10.1515\/med-2023-0838","volume":"18","author":"P Wang","year":"2023","unstructured":"Wang P, Zhang L, Guo Q, Zhao L, Hao Y. Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis. Open Med (Wars). 2023;18(1):20230838.","journal-title":"Open Med (Wars)"},{"issue":"10","key":"551_CR78","doi-asserted-by":"publisher","first-page":"e15354","DOI":"10.1111\/1756-185X.15354","volume":"27","author":"Y Feng","year":"2024","unstructured":"Feng Y, Chen J, Yang X, Liu J, Cao X, Zhang Y, Wu Z. Efficacy and safety of oral versus intravenous cyclophosphamide in treatment of connective tissue disease-related interstitial lung disease. Int J Rheum Dis. 2024;27(10):e15354.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"551_CR79","doi-asserted-by":"publisher","first-page":"e15226","DOI":"10.1111\/1756-185X.15226","volume":"27","author":"D Liu","year":"2024","unstructured":"Liu D, Zhang S, Hu N, Zhao H, Sun H. Clinical features analysis and treatment of systemic lupus erythematosus related interstitial lung disease. Int J Rheum Dis. 2024;27(6):e15226.","journal-title":"Int J Rheum Dis"},{"issue":"18","key":"551_CR80","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"551_CR81","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476\u201386.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"551_CR82","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.42075","volume":"74","author":"EL Matteson","year":"2022","unstructured":"Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, et al. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. Arthritis Rheumatol. 2022;74(6):1039\u201347.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"551_CR83","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0961203317722411","volume":"27","author":"M Deeb","year":"2018","unstructured":"Deeb M, Tselios K, Gladman DD, Su J, Urowitz MB. Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience. Lupus. 2018;27(3):365\u201371.","journal-title":"Lupus"},{"issue":"5","key":"551_CR84","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1053\/sarh.2002.32555","volume":"31","author":"MY Karim","year":"2002","unstructured":"Karim MY, Miranda LC, Tench CM, Gordon PA, D\u2019Cruz DP, Khamashta MA, Hughes GR. Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum. 2002;31(5):289\u201398.","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"551_CR85","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1191\/0961203305lu2186cr","volume":"14","author":"KT Oud","year":"2005","unstructured":"Oud KT, Bresser P, ten Berge RJ, Jonkers RE. The shrinking lung syndrome in systemic lupus erythematosus: improvement with corticosteroid therapy. Lupus. 2005;14(12):959\u201363.","journal-title":"Lupus"},{"issue":"33","key":"551_CR86","doi-asserted-by":"publisher","first-page":"e4626","DOI":"10.1097\/MD.0000000000004626","volume":"95","author":"H Borrell","year":"2016","unstructured":"Borrell H, Narvaez J, Alegre JJ, Castellvi I, Mitjavila F, Aparicio M, et al. Shrinking lung syndrome in systemic lupus erythematosus: A case series and review of the literature. Med (Baltim). 2016;95(33):e4626.","journal-title":"Med (Baltim)"},{"issue":"10","key":"551_CR87","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.autrev.2016.07.021","volume":"15","author":"L Duron","year":"2016","unstructured":"Duron L, Cohen-Aubart F, Diot E, Borie R, Abad S, Richez C, et al. Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev. 2016;15(10):994\u20131000.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"551_CR88","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222\u201333.","journal-title":"Arthritis Rheum"},{"issue":"10381","key":"551_CR89","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401(10381):1001\u201310.","journal-title":"Lancet"},{"issue":"10381","key":"551_CR90","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, Dorner T, Tanaka Y, Morand EF, Kalunian KC, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401(10381):1011\u20139.","journal-title":"Lancet"},{"issue":"2","key":"551_CR91","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2023;75(2):242\u201352.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"551_CR92","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","volume":"69","author":"ME Clowse","year":"2017","unstructured":"Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczynski P, et al. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. Arthritis Rheumatol. 2017;69(2):362\u201375.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"551_CR93","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","volume":"52","author":"DJ Wallace","year":"2013","unstructured":"Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, et al. Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). 2013;52(7):1313\u201322.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"551_CR94","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/0961203308100659","volume":"18","author":"E Rosenbaum","year":"2009","unstructured":"Rosenbaum E, Krebs E, Cohen M, Tiliakos A, Derk CT. The spectrum of clinical manifestations, outcome and treatment of pericardial tamponade in patients with systemic lupus erythematosus: a retrospective study and literature review. Lupus. 2009;18(7):608\u201312.","journal-title":"Lupus"},{"issue":"42","key":"551_CR95","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921\u201364.","journal-title":"Eur Heart J"},{"issue":"4","key":"551_CR96","first-page":"334","volume":"1","author":"F Oliveira Pinheiro","year":"2022","unstructured":"Oliveira Pinheiro F, Seabra Rato M, Madureira P, Paiva M, Costa L. Recurrent Lupus Pericarditis Treated with Anakinra - a Case Report. ARP Rheumatol. 2022;1(4):334\u20135.","journal-title":"ARP Rheumatol"},{"issue":"1","key":"551_CR97","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa2027892","volume":"384","author":"AL Klein","year":"2021","unstructured":"Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. N Engl J Med. 2021;384(1):31\u201341.","journal-title":"N Engl J Med"},{"key":"551_CR98","doi-asserted-by":"crossref","unstructured":"Kamata Y, Minota S. Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep. 2012;2012.","DOI":"10.1136\/bcr-2012-007834"},{"key":"551_CR99","doi-asserted-by":"crossref","unstructured":"Ocampo V, Haaland D, Legault K, Mittoo S, Aitken E. Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous. BMJ Case Rep. 2016;2016.","DOI":"10.1136\/bcr-2016-215423"},{"issue":"2","key":"551_CR100","first-page":"e22639","volume":"14","author":"S Mukkera","year":"2022","unstructured":"Mukkera S, Mannem M, Chamarti K, Pillarisetty L, Vulasala SS, Alahari L, et al. Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report. Cureus. 2022;14(2):e22639.","journal-title":"Cureus"},{"issue":"4","key":"551_CR101","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0961203314520844","volume":"23","author":"M Juptner","year":"2014","unstructured":"Juptner M, Zeuner R, Schreiber S, Laudes M, Schroder JO. Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment. Lupus. 2014;23(4):428\u201330.","journal-title":"Lupus"},{"issue":"1","key":"551_CR102","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13075-019-1868-0","volume":"21","author":"HA Chen","year":"2019","unstructured":"Chen HA, Hsu TC, Yang SC, Weng CT, Wu CH, Sun CY, Lin CY. Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study. Arthritis Res Ther. 2019;21(1):82.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"551_CR103","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s10067-018-4056-8","volume":"37","author":"SZ Xu","year":"2018","unstructured":"Xu SZ, Yan L, Li XP, Li XM, Shuai ZW, Leng RX, et al. Features associated with pulmonary arterial hypertension in Chinese hospitalized systemic lupus erythematosus patients. Clin Rheumatol. 2018;37(6):1547\u201353.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"551_CR104","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1055\/s-2003-41089","volume":"24","author":"LT Tanoue","year":"2003","unstructured":"Tanoue LT. Pulmonary hypertension in the collagen vascular diseases. Semin Respir Crit Care Med. 2003;24(3):287\u201396.","journal-title":"Semin Respir Crit Care Med"},{"issue":"38","key":"551_CR105","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"key":"551_CR106","doi-asserted-by":"crossref","unstructured":"Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4).","DOI":"10.1183\/13993003.01325-2024"},{"key":"551_CR107","doi-asserted-by":"crossref","unstructured":"Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grunig E, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1).","DOI":"10.1183\/13993003.02311-2021"},{"key":"551_CR108","doi-asserted-by":"publisher","first-page":"618486","DOI":"10.3389\/fmed.2021.618486","volume":"8","author":"J Qu","year":"2021","unstructured":"Qu J, Li M, Zeng X, Zhang X, Wei W, Zuo X, et al. Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. Front Med (Lausanne). 2021;8:618486.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"551_CR109","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1378\/chest.11-0676","volume":"141","author":"RL Benza","year":"2012","unstructured":"Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354\u201362.","journal-title":"Chest"},{"issue":"13","key":"551_CR110","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021;384(13):1204\u201315.","journal-title":"N Engl J Med"},{"issue":"16","key":"551_CR111","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(16):1478\u201390.","journal-title":"N Engl J Med"},{"key":"551_CR112","doi-asserted-by":"crossref","unstructured":"Preston IR, Badesch D, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, et al. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J. 2025;66(1).","DOI":"10.1183\/13993003.01435-2024"},{"issue":"20","key":"551_CR113","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","volume":"392","author":"M Humbert","year":"2025","unstructured":"Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025;392(20):1987\u20132000.","journal-title":"N Engl J Med"},{"issue":"16","key":"551_CR114","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa2508170","volume":"393","author":"VV McLaughlin","year":"2025","unstructured":"McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. N Engl J Med. 2025;393(16):1599\u2013611.","journal-title":"N Engl J Med"},{"key":"551_CR115","doi-asserted-by":"crossref","unstructured":"Yokoyama YM, Watanabe R, Yamaguchi T, Ishihara R, Shiomi M, Fujita Y, et al. Connective tissue disease-associated pulmonary arterial hypertension: current therapeutic strategies and future prospects. Biomolecules. 2026;16(1).","DOI":"10.3390\/biom16010140"},{"key":"551_CR116","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jama.1964.03070150014003","volume":"190","author":"EL Dubois","year":"1964","unstructured":"Dubois EL, Tuffanelli DL. Clinical Manifestations of Systemic Lupus Erythematosus. Computer Analysis of 520 Cases. JAMA. 1964;190:104\u201311.","journal-title":"JAMA"},{"issue":"2","key":"551_CR117","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00296-016-3630-0","volume":"37","author":"Y Liang","year":"2017","unstructured":"Liang Y, Leng RX, Pan HF, Ye DQ. The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatol Int. 2017;37(2):305\u201311.","journal-title":"Rheumatol Int"},{"issue":"8","key":"551_CR118","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/rheumatology\/41.8.876","volume":"41","author":"MY Karim","year":"2002","unstructured":"Karim MY, Alba P, Cuadrado MJ, Abbs IC, D\u2019Cruz DP, Khamashta MA, Hughes GR. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford). 2002;41(8):876\u201382.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"551_CR119","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/ard.56.6.382","volume":"56","author":"S Gansauge","year":"1997","unstructured":"Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis. 1997;56(6):382\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"551_CR120","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1136\/ard.2005.044487","volume":"65","author":"KP Ng","year":"2006","unstructured":"Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis. 2006;65(7):942\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"551_CR121","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s002960000053","volume":"19","author":"M Meissner","year":"2000","unstructured":"Meissner M, Sherer Y, Levy Y, Chwalinska-Sadowska H, Langevitz P, Shoenfeld Y. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int. 2000;19(5):199\u2013201.","journal-title":"Rheumatol Int"},{"issue":"4","key":"551_CR122","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1191\/096120399678847759","volume":"8","author":"Y Sherer","year":"1999","unstructured":"Sherer Y, Langevitz P, Levy Y, Fabrizzi F, Shoenfeld Y. Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin. Lupus. 1999;8(4):324\u20137.","journal-title":"Lupus"},{"issue":"5","key":"551_CR123","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/00005792-197509000-00003","volume":"54","author":"RA Matthay","year":"1975","unstructured":"Matthay RA, Schwarz MI, Petty TL, Stanford RE, Gupta RC, Sahn SA, Steigerwald JC. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Med (Baltim). 1975;54(5):397\u2013409.","journal-title":"Med (Baltim)"},{"issue":"8","key":"551_CR124","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/archinte.1981.00340080117027","volume":"141","author":"JP Isbister","year":"1981","unstructured":"Isbister JP, Ralston M, Hayes JM, Wright R. Fulminant lupus pneumonitis with acute renal failure and RBC aplasia. Successful management with plasmapheresis and immunosuppression. Arch Intern Med. 1981;141(8):1081\u20133.","journal-title":"Arch Intern Med"},{"issue":"14","key":"551_CR125","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1177\/0961203314548713","volume":"23","author":"YJ Chen","year":"2014","unstructured":"Chen YJ, Tseng JJ, Yang MJ, Tsao YP, Lin HY. Acute respiratory distress syndrome in a pregnant woman with systemic lupus erythematosus: a case report. Lupus. 2014;23(14):1528\u201332.","journal-title":"Lupus"},{"issue":"9","key":"551_CR126","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/09612033231188034","volume":"32","author":"F Triboulet","year":"2023","unstructured":"Triboulet F, Guerin E, Boussouar S, Hekimian G, Pha M, Rouvier P, et al. Systemic lupus erythematosus-related acute lung disease. Lupus. 2023;32(9):1117\u201322.","journal-title":"Lupus"},{"key":"551_CR127","doi-asserted-by":"crossref","unstructured":"Claridge S, Das P, Dorling A, Robson MG. Plasmapheresis as rescue therapy for systemic lupus erthyematosus-associated diffuse alveolar haemorrhage. BMJ Case Rep. 2011;2011.","DOI":"10.1136\/bcr.02.2011.3893"},{"issue":"6","key":"551_CR128","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2559.2004.01896.x","volume":"44","author":"D Tansey","year":"2004","unstructured":"Tansey D, Wells AU, Colby TV, Ip S, Nikolakoupolou A, du Bois RM, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44(6):585\u201396.","journal-title":"Histopathology"},{"issue":"1","key":"551_CR129","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45\u201354.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"551_CR130","doi-asserted-by":"publisher","first-page":"e15110","DOI":"10.1111\/1756-185X.15110","volume":"27","author":"AC Esteves","year":"2024","unstructured":"Esteves AC, Mendes B, Assuncao H, Ines LS. Combination treatment with rituximab and belimumab in shrinking lung syndrome in systemic lupus erythematosus. Int J Rheum Dis. 2024;27(3):e15110.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"551_CR131","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-026-00551-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00551-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00551-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:07:09Z","timestamp":1785888429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-026-00551-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1186\/s42358-026-00551-1","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"47"}}